Viral infections in obstructive airway diseases

Current Opinion in Pulmonary Medicine

Volumn 9, Issue 2, 2003, Pages 111-116

  Seemungal, Terence A R ^a   Wedzicha, Jadwiga A ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ASTHMA; DISEASE ASSOCIATION; DISEASE EXACERBATION; DISEASE SEVERITY; HUMAN; NONHUMAN; OBSTRUCTIVE AIRWAY DISEASE; PATHOPHYSIOLOGY; REVIEW; VIRUS INFECTION;

ADENOVIRIDAE; AIRWAY OBSTRUCTION; ASTHMA; BACTERIAL INFECTIONS; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY SYNCYTIAL VIRUSES; RHINOVIRUS; VIRUS DISEASES;

EID: 0037362028     PISSN: 10705287     EISSN: None     Source Type: Journal    
DOI: 10.1097/00063198-200303000-00004     Document Type: Review

References (41)

1. National Heart, Lung, and Blood Institute: Expert Panel Report 2: Guidelines for the Diagnosis and Management of Asthma. Bethesda, MD: National Institutes of Health; 1997.
2. National Heart, Lung, and Blood Institute: Global initiative for chronic obstructive lung disease. Bethesda, MD: National Institutes of Health; 2001.
3. Seemungal TAR, Donaldson GC, Paul EA, et al: Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998, 157:1418-1422.
4. Anthonisen NR, Manfreda J, Warren CP, et al: Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987, 106:196-204.
5. 1, 1.07 L). Viruses were detected by reverse transcriptase PCR, virus culture of nasal aspirates, and serology in 66 (39.2%) of 168 exacerbations; of these, RV was present in 58.2% of viral exacerbations or 22.9% of all exacerbations. RSV occurred in 14.2% exacerbations. Viral exacerbations were significantly associated with a higher total symptom score at onset, symptoms of a cold, sore throat, increased dyspnea with a cold, a rise in plasma fibrinogen, and a slower median recovery time to baseline symptoms (13 vs 6 days, P = 0.006). Non-RSV viruses were detected in 11 (16%) and RSV in 16 (23.5%) of 68 stable COPD patients with RSV detection associated with higher stable plasma fibrinogen, serum IL-6, and baseline arterial carbon dioxide.
6. 1 and, in Group 2, with a higher mean (SD) exacerbation frequency (2.03 [1.12] vs 1.43 [1.32]). Thirty-four PCR positive patients had acute exacerbations and were treated with azithromycin for 42 days. C. pneumoniae reactivation occurred in 2 of 34 patients (by serology). The rate of C. pneumoniae clearance from the blood was 59% at 42 days but only 29% at follow-up at 72 days.
7. Jeffery PK: Structural and inflammatory changes in COPD: a comparison with asthma. Thorax 1998, 53:129-136.
8. Bhowmik A, Seemungal TAR, Sapsford RJ, et al: Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations. Thorax 2000, 55:114-120.
9. 1% predicted at follow-up (70.1 vs 86.5). Those with virus infection showed increased sputum neutrophils, increased neutrophils elastase, and the latter was related to elevated sputum lactate dehydrogenase. Both groups had elevated eosinophil cationic protein.
10. Johnston SL, Pattemore PK, Sanderson G, et al: Community study of role of viral infections in exacerbations of asthma in 9-11-year-old children. BMJ 1995, 310:1225-1229.
11. Nicholson KG, Kent J, Ireland DC: Respiratory viruses and exacerbations of asthma in adults. BMJ 1993,307:982-986.
12. Smith CA, Hodina RL, Brown TF, et al: Respiratory syncytial virus: an association with severe asthma exacerbations in children of all ages. Ped Asthma Allergy & Immunol 2001, 15:69-75.
13. Zhao J, Takamura M, Yamaoka A, et al: Altered eosinophil levels as a result of viral infection in asthma exacerbation in childhood. Ped Allergy & Immunol 2002, 13:47-50.
14. Greenberg SB, Allen M, Wilson J, et al: Respiratory viral infection in adults with and without chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000, 162:167-173.
15. 20 in controls.
16. Seemungal TAR, Donaldson GC, Bhowmik A, et al: Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000, 161:1608-1618.
17. Gern JE, Galagan DM, Jarjour NN, et al: Detection of rhinovirus RNA in lower airway cells during experimentally induced infection. Am J Respir Crit Care Med 1997, 155:1159-1161.
18. Seemungal TAR, Harper-Owen R, Bhowmik A, et al: Detection of rhinovirus in induced sputum at exacerbation of chronic obstructive pulmonary disease. Eur Respir J 2000, 16:677-683.
19. Johnston SL, Papi A, Bates PJ, et al: Low grade rhinovirus infection induces a prolonged release of IL-8 in pulmonary epithelium. J Immunol 1998, 160:6172-6181.
20. Subauste MC, Jacoby DB, Richards SM, et al: Infection of a human respiratory epithelial cell line with rhinovirus. J Clin Invest 1995, 96:549-557.
21. Zhu Z, Tang W, Ray A: Rhinovirus stimulation of Interleukin-6 in vivo and in vitro. J Clin Invest 1996, 97:421-430.
22. Grunstein MM, Hakonarson H, Whelan R, et al: Rhinovirus elicits pro-asthmatic changes in airway responsiveness independently of viral infection. J Allergy Clin Immunol 2001, 108:997-1004. • This was an in vitro study of isolated airway smooth muscle tissues, and airway smooth muscle cells were inoculated with either infectious or noninfectious (UV-irradiated) RV-16 and RV-2, belonging to the major and minor groups of RV serotypes respectively. RV-2 had no effect but RV-16 inoculation (infectious or noninfectious) was associated with enhanced contractility and impaired relaxation to cholinergic and beta-adrenergic agonists respectively with increased G1 protein expression and release of the proinflammatory cytokines IL-5 and IL-1β. However, pretreatment of airway smooth muscle with neutralizing antibody to ICAM-1 (host receptor for the major group of RV-16) completely aborted the above responses.
23. Saint S, Bent S, Vittinghoff E, et al: Antibiotics in chronic obstructive pulmonary disease exacerbations. A meta-analysis. JAMA 1995, 273:957-960.
24. Suzuki T, Yamaya M, Sekizawa K, et al: Erythromycin inhibits rhinovirus infection in cultured human tracheal epithelial cells. Am J Respir Crit Care Med 2002, 165:1113-1118.
25. Hahn DL, Dodge RW, Glubjatnikov R: Association of Chlamydia pneumoniae (strain TWAR) infection with wheezing, asthmatic bronchitis and adult onset asthma. JAMA 1991, 266:225-230.
26. Cook PJ, Davies P, Tunnicliffe W, et al: Chlamydia pneumoniae and asthma. Thorax 1998, 53:254-259.
27. Black PN, Scicchitano R, Jenkins CR, et al: Serological evidence of infection with Chlamydia pneumoniae is related too severity of asthma. Eur Respir J 2000, 15:254-259.
28. Blasi F, Legnani D, Lombardo VM, et al: Chlamydia pneumoniae infection in acute exacerbations of COPD. Eur Respir J 1993, 6:19-22.
29. Cunningham AF, Johnston SL, Julious SA, et al: Chronic Chlamydia pneumoniae infection and asthma exacerbations in children. Eur Respir J 1998, 11:345-349.
30. Seemungal TA, Wedzicha JA, MacCallum PK, et al: Chlamydia pneumoniae and COPD exacerbation. Thorax 2002, 57:1087-1089.
31. Gump DW, Phillips CA, Forsyth BR, et al: Role of infection in chronic bronchitis. Am Rev Respir Dis 1976, 113:465-473.
32. Smith CB, Golden CA, Kanner RE, et al: Association of viral and Mycoplasma pneumoniae infections with acute respiratory illness in patients with chronic obstructive pulmonary diseases. Am Rev Respir Dis 1980, 121:225-232.
33. Donaldson GC, Seemungal TAR, Bhowmik A, et al: Relation between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002, 57:847-852.
34. Von Hertzen L, Alakarppa H, Koskinen R, et al: Chlamydia pneumoniae infection in patients with chronic obstructive pulmonary disease. Epidemiol Infect 1997, 118:155-164.
35. Wu L, Skinner SJM, Lambie N, et al: Immunohistochemical staining for Chlamydia pneumoniae is increased in lung tissue from subjects with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000, 162:1148-1151.
36. Matsuse T, Hayashi S, Kuwano K, et al: Latent adenoviral infection in the pathogenesis of chronic airway obstruction. Am Rev Respir Dis 1992, 146:177-184.
37. Hogg JC: Role of latent viral infections in chronic obstructive pulmonary disease and asthma. Am J Respir Crit Care Med 2001, 164:S71-S75.
38. Macek V, Sorli J, Kopriva S, et al: Persistent adenoviral infection and chronic infection in children. Am J Respir Crit Care Med 1994, 150:7-10.
39. Retamales I, Eliott WM, Meshi B, et al: The amplification of inflammation in emphysema and its association with adenoviral infection. Respir Crit Care Med 2001, 164:469-473.
40. Higashimoto Y, Elliot WM, Behzad AR, et al: Inflammatory mediator expression by adenovirus E1 A-transfected bronchial epithelial cells. Am J Respir Crit Care Med 2002, 200-207. • This was a study of resected lung tissue of three patients. Human bronchial epithelial cells were transfected with adenovirus E1A or control plasmid. Lipopolysaccharide stimulation of the E1A-transfected cells increased ICAM-1 and IL-8 mRNA and protein expression, ICAM-1 promoter activity, TGF-β1 mRNA and protein, and NF-κB-binding activity of nuclear extracts compared with control cells from the same patient. Thus E1A protein upregulates mediators relevant to the pathogenesis of COPD.
41. Patel SI, Seemungal TAR, Wilks M, et al: Relation of Haemophitus influenzae colonization to exacerbation frequency in COPD. Thorax 2002, 57:759-764.